Radioimmunotherapy was combined with or without low-dose paclitaxel in patients with mCRPC and breast cancer. In two patients with mCRPC who received m170 (MUC-1 monoclonal antibody) linked to indium-111, a 50% decline in PSA level was shown which lasted 2 months, and two patients described a decrease in bone pain (48). Here, MUC1 is linked to breast cancer.